Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Drug Information

Target Indication

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

JNGHF

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Related Pipeline

KNEE OSTEOARTHRITIS

Postoperative Analgesia

Carcinoma, Hepatocellular

PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

Pain